Carol Wysham reported on 978 patients with type 2 diabetes in the 52-week, phase III AWARD-1 trial who were randomized to dulaglutide at 1.5 or 0.75 mg, the injectable GLP-1 agonist exenatide at 10 mcg twice daily, or placebo
In addition, the efficacy and stability of the compound have also been improved
The same study found that the most common reasons patients stop GLP-1 therapy are adverse effects (52%), medication shortages (33%), and cost (25%)
Available from: Central Drugs Standard Control Organisation
Studies on mesotherapy delivery show approximately 91.4 new hairs versus 22.2 hairs (topical) after 12 weeks, with over 80% of patients showing greater than 50% improvement compared to 4.5% with topical alone
How to Use our Semaglutide + BioBoost Injections at home To use Semaglutide + BioBoost injections at home, start by washing your hands and cleaning the vials rubber top with an alcohol swab